Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Spero Therapeutics (SPRO) over the last 8 years, with Q3 2025 value amounting to $12.6 million.

  • Spero Therapeutics' Non-Current Deffered Revenue rose 611.81% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 611.81%. This contributed to the annual value of $12.2 million for FY2024, which is 1287.76% up from last year.
  • As of Q3 2025, Spero Therapeutics' Non-Current Deffered Revenue stood at $12.6 million, which was up 611.81% from $12.6 million recorded in Q2 2025.
  • Over the past 5 years, Spero Therapeutics' Non-Current Deffered Revenue peaked at $23.8 million during Q3 2023, and registered a low of $8.8 million during Q4 2021.
  • Over the past 5 years, Spero Therapeutics' median Non-Current Deffered Revenue value was $12.2 million (recorded in 2024), while the average stood at $13.5 million.
  • As far as peak fluctuations go, Spero Therapeutics' Non-Current Deffered Revenue tumbled by 5946.19% in 2024, and later soared by 3910.4% in 2025.
  • Over the past 5 years, Spero Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $8.8 million in 2021, then increased by 10.87% to $9.7 million in 2022, then rose by 11.13% to $10.8 million in 2023, then increased by 12.88% to $12.2 million in 2024, then rose by 2.91% to $12.6 million in 2025.
  • Its Non-Current Deffered Revenue stands at $12.6 million for Q3 2025, versus $12.6 million for Q2 2025 and $12.6 million for Q1 2025.